IONIS reveals positive IgAN interim data
The company announced that partner Roche's trial met its primary endpoint, offering a treatment option that may prevent kidney failure.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed